Weekly Issue — 2025-11-09

The framework is an evolution of the older Life's Simple 7. It keeps the familiar pillars — diet, physical activity, nicotine exposure, body mass index, blood lipids, blood glucose, and blood pressure — and adds an eighth that many parents will recognize as the missing piece: sleep. Each metric is now scored on a granular scale, then averaged into a single number from 0 to 100, with 80 and above considered 'high' cardiovascular health.

That granularity matters. A 14-point score lumps people into broad buckets; a 100-point score can show you that your blood pressure is excellent, your activity is middling, and your sleep is dragging the whole average down. For a tired parent, that's not a verdict — it's a map.

To see how the new score plays out in real life, researchers applied it to CONSTANCES, a nationwide French cohort of more than 191,000 adults aged 18 to 69. The participants were free of prior cardiovascular disease and weighted to represent roughly 45 million people. It's one of the largest looks yet at how Life's Essential 8 distributes across a general adult population outside the United States.

The headline number is sobering and useful at once: the average score was about 66 out of 100. Not failing, not flourishing — squarely in the middle. Women averaged meaningfully higher than men, and only a small slice of adults landed in the 'high' cardiovascular health band that the AHA defines as 80 or above.

For readers who suspect that 'optimal' heart health is the quiet norm among health-conscious peers, the data offer a gentle corrective. High cardiovascular health is rare. That's not a reason for guilt; it's a reason to be realistic about where small, consistent shifts can move the needle.

The decision to add sleep to the score is the part of this update parents tend to feel in their bones. Short or fragmented sleep nudges blood pressure, appetite hormones, and glucose regulation in directions that, repeated over years, show up on a cardiologist's chart. The AHA's framework recognizes that a person averaging five hours a night is carrying a different cardiovascular load than someone getting seven — even if everything else looks identical.

That doesn't mean the answer is to chase eight perfect hours while a newborn is in the house. It means sleep counts as part of the picture, and that small wins — an earlier lights-out two nights a week, a partner taking the dawn shift on weekends — are legitimately cardio-protective, not just nice-to-haves.

Life's Essential 8 is designed to be self-assessable, with the caveat that three of the eight pillars — lipids, glucose, and blood pressure — need real measurements. Many readers already have these from a recent physical; if not, this is the kind of audit a primary care visit is built for.

The other five — diet pattern, physical activity, nicotine and vaping exposure, BMI, and sleep duration — you can estimate at the kitchen table. The point isn't precision to the decimal. It's noticing which pillar is doing the heavy lifting and which one is quietly costing you points.

The French data are a useful reality check here. If your score lands in the 60s, you are in the company of the average adult in a large, well-characterized European population. The question worth asking isn't 'how do I get to 100?' It's 'which single pillar, if I nudged it for the next three months, would move my number the most?'

What's quietly radical about Life's Essential 8 isn't any single pillar. It's the suggestion that cardiovascular health is a composite — that a great sleep stretch can partly offset a stressful eating week, that a daily walk earns real points even when the gym is a fantasy, and that the parts of life that feel least medical, like rest, are part of the medicine. For parents running on fumes, that reframing might be the most useful thing the new score offers: permission to count the small wins, and a number that quietly counts them back.

The paper, published in Advances in Gerontology, applied PRISMA screening across PubMed, Scopus, Web of Science, and eLibrary to studies published between 2010 and 2025. The headline finding is that microplastic exposure significantly increased reactive oxygen species — ROS, the unstable molecules implicated in cellular wear-and-tear — with a standardized mean difference of 0.56 (95% CI 0.45–0.67), a moderate and statistically robust effect, according to the authors' pooled analysis.

That is a meaningful number, but it deserves context before it becomes a headline on a supplement bottle. A standardized mean difference of 0.56 is the kind of effect size researchers call moderate: large enough to be real, small enough that individual studies could plausibly miss it. And critically, the meta-analysis aggregates across model systems — cell cultures, invertebrates, rodents — rather than across long-term human cohorts, which simply don't exist yet for an exposure this newly recognized.

Aging biomarkers are not aging itself. They are proxies — measurable molecular fingerprints that tend to track with the deterioration we eventually see in tissues and organs. ROS sits near the top of that list because oxidative stress is one of the older, better-characterized mechanisms in the biology of aging: when antioxidant defenses can't keep pace with reactive oxygen production, lipids, proteins, and DNA accumulate damage. The meta-analysis reports that microplastics shifted this balance in a consistent direction across the studies pooled.

Consistency matters. Individual microplastic studies have been criticized — fairly — for using particle concentrations that dwarf real-world environmental exposure, for short timeframes, and for endpoints chosen post-hoc. A meta-analysis can't fix any of those problems in the underlying papers, but it can tell you whether the direction of effect holds when you stop cherry-picking. Here, it does.

It is tempting, given the size of the pooled dataset, to skip ahead to the practical question: should you be doing something about microplastics to slow your own aging? The honest answer from this paper alone is that we are not there. The analysis establishes that microplastic exposure modulates aging biomarkers across model systems; it does not establish that reducing your bottled-water intake will measurably extend your lifespan, nor that any supplement on the market meaningfully offsets the exposure.

What it does do is unify a literature that, until recently, looked like a collection of anecdotes in fish and cell lines. A moderate, directionally consistent effect across 1,400 observations is the kind of foundation regulators and longer-term human studies tend to build on. It is also the kind of finding that wellness marketing will, predictably, race ahead of. Expect a wave of "microplastic detox" products in the next 18 months. None of them are supported by this paper.

The most useful thing a meta-analysis like this does is sharpen the questions for the next round of research. Which particle sizes and polymer types drive the effect? At what cumulative exposure does the biomarker shift translate into functional decline? Do antioxidant pathways already in clinical use blunt the response, or merely the readout? The authors frame their work as a foundation for further investigation into microplastics as a modulator of longevity — which is the right register. Moderate evidence of a mechanism is not the same as evidence of an intervention.

For now, the most defensible reading is this: microplastics appear to perturb the same oxidative-stress machinery that aging research has spent decades characterizing, and the perturbation is consistent enough across studies to take seriously. That is a real finding. It is not a reason to buy anything.

Here's the framing. Exercise is, at the cellular level, a controlled stress. You generate reactive oxygen species, and your cells respond by activating NRF2 — a master transcription factor that turns on antioxidant and detoxification genes. That redox response is a big part of why training makes you more resilient over time. The problem: as people age, that signal gets blunted. The hormetic punch lands softer.

That's the gap a 2025 GeroScience study set out to probe. Researchers recruited 25 older adults — average age 67 — and had them do a 30-minute cycling bout. They drew blood before and immediately after, isolated immune cells (PBMCs), and treated them with or without sulforaphane in a dish. Four conditions: control, sulforaphane alone, exercise alone, and exercise plus sulforaphane. Then they measured NRF2 activation and the downstream antioxidant genes it controls — NQO1, HO-1, GR, GCLC.

All three active conditions beat control. But the combination — acute exercise plus ex vivo sulforaphane — produced the largest NRF2 activation. In other words, in this small mechanistic study, the phytochemical didn't replace the exercise stimulus. It amplified it.

Read that paragraph again, because the design is doing a lot of work. The exercise happened in the human. The sulforaphane was added to the cells in a dish afterward. That's an elegant way to isolate mechanism, but it's not the same as proving that swallowing a broccoli-sprout capsule before your next ride will translate into better long-term adaptation. The authors are essentially saying: the biology is plausible, the signal is there, the older-adult redox deficit appears bridgeable. Whether oral sulforaphane in real humans, taken around real training, produces meaningful functional gains — that trial hasn't been run.

This is the part the supplement world routinely skips. A mechanistic win in PBMCs is a green light to keep investigating, not a green light to market.

Now the turmeric question. A 2025 narrative review in Nutrients synthesizes a quarter-century of work on curcumin and the aging brain — Alzheimer's, Parkinson's, post-stroke cognitive impairment. The mechanistic story is genuinely impressive. Curcumin appears to dampen oxidative stress, suppress inflammatory drivers like NF-κB, COX-2, and iNOS, modulate apoptosis, interfere with amyloid-beta aggregation, and upregulate BDNF — the neurotrophic factor that supports neuronal plasticity. It also touches autophagy and mitophagy, the cellular housekeeping pathways that decline with age.

In rodent models of Alzheimer's, Parkinson's, and ischemic stroke, the review notes dose-dependent neuroprotective effects, with results meaningfully improved when the compound is delivered via nanoparticle-based formulations. That last detail is the catch — and it's a big one.

Curcumin's oral bioavailability is famously poor. The molecule that does beautiful things in a Petri dish or a targeted delivery vehicle struggles to reach the brain in useful concentrations when you eat it. The review is candid about this: clinical translation has been limited precisely because the pharmacokinetics don't cooperate. Standard turmeric powder, even in generous amounts, isn't the same intervention as the engineered formulations producing the preclinical wins.

If you're the kind of lifter who reads abstracts, here's the honest synthesis. Sulforaphane has a plausible, mechanistically grounded case as an adjunct to exercise in older adults, supported by a small in vivo–ex vivo human study. Curcumin has 25 years of preclinical neuroprotective mechanism behind it and a real translational ceiling imposed by bioavailability. Neither finding clears the bar for confident clinical recommendations. Both clear the bar for serious continued research.

What it doesn't mean: that capsules can substitute for training, sleep, or protein intake. What it does mean: the food matrix these compounds come from — cruciferous vegetables, turmeric used liberally in cooking — is a low-risk, high-reward dietary choice on its own merits, independent of any supplement marketing claim. Before adding a concentrated extract on top of medications or training plans, talk to a clinician who knows your bloodwork.